Conclusion
Allergic reactions to therapies with human urinary-derived gonadotropins are of a low incidence. They may, however, have serious consequences as reported in our case study. In our opinion, they are probably related to the presence of copurified urinary proteins. One might hypothesize that highly purified and/or recombinant human gonadotropins will reduce this incidence yet further in the future.
This is a preview of subscription content, log in via an institution to check access.
References
Keitel W, Gutschmidt HJ, Rosam W: Nil nocere. Allergic therapeutic agents side effects due to heterogenic follicle stimulating hormone (FSH). Munch Med Wochenschr 1968;110:707–709
Li TC, Hindle JE: Adverse local reaction to intramuscular injections of urinary-derived gonadotrophins. Hum Reprod 1993;8:1835–1836
Watson AJ: Adverse effects of therapy for the correction of anemia in hemodialysis. Semin Nephrol 1989;9:30–34
Mannaerts B, Shoham Z, Schoot B, Bouchard P, Harlin J, Fauser B, Jacobs H, Rombout F, Coelingh Bennink H: Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle stimulating hormone (Org. 32489) in gonadotropin-deficient volunteers. Fertil Steril 1993;59:108–114
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harika, G., Gabriel, R., Quereux, C. et al. Hypersensitization to human menopausal gonadotropins with anaphylactic shock syndrome during a fifth in vitro fertilization cycle. J Assist Reprod Genet 11, 51–53 (1994). https://doi.org/10.1007/BF02213699
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02213699